Nasdaq
$2.61▼ 1.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $31.2MShares out 12.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.25Pre-market26.09.25 21:4110-KEarnings#●●●#●●●
Incannex Healthcare Inc.
Incannex Healthcare Inc. has filed its Annual Report (Form 10-K) for the fiscal year ended June 30, 2026. As of September 24, 2026, the company had 12,544,627 shares of common stock issued and outstanding, while continuing its clinical development and regulatory pathways for drug candidates including IHL-42X, PSX-001, and IHL-675A.…more
$2.61-1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9Pre-market26.09.09 20:308-KKey event
Incannex Healthcare Inc.
Incannex Healthcare has commenced patient dosing for its Phase 2 DReAMzz study of IHL-42X for obstructive sleep apnea and secured a U.S. patent for the candidate expiring in 2040. As of August 31, 2026, the company maintains a strong financial position with approximately $70 million in cash and zero debt.…more
$2.61-1.13%vs prev closeView filingShare - 8.25Pre-market26.08.25 20:308-KKey event
Incannex Healthcare Inc.
Incannex Healthcare has successfully dosed the first patient in its Phase 2 DReAMzz dose-optimization study for IHL-42X, an oral drug candidate for obstructive sleep apnea. The study is being conducted across 14 U.S. sites, building upon positive Phase 2 RePOSA results that showed up to 83% reductions in AHI and the drug's FDA Fast Track designation to support progression toward Phase 3 development.…more
$2.61-1.13%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.25Pre-market26.08.25 21:46#●●●#●●●#●●●
Incannex Begins Phase 2 Dosing for Sleep Apnea Drug IHL-42X
Incannex Healthcare has commenced dosing the first patient in its Phase 2 dose-optimization study for IHL-42X, a treatment candidate for obstructive sleep apnea. This milestone aims to refine dosing regimens and strengthen the clinical foundation for upcoming Phase 3 trials.…more
$2.61-1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.25Pre-market26.08.25 21:47
●●●●●●●● ●●●●● ●●●●●●
Incannex Healthcare has initiated the first patient dosing for its Phase 2 DReAMzz dose-optimization study of IHL-42X for obstructive sleep apnea. The study is being conducted across 14 clinical sites in the United States to determine optimal dosing.…more
$2.61-1.13%vs prev closeShareBenzinga - 7.23Pre-market26.07.23 21:00
●●●●●●●● ●●●●● ●●●●●●
Incannex Healthcare는 수면무호흡증 치료제 IHL-42X의 임상 2상 DReAMzz 연구 대상자 모집을 시작했습니다. FDA 패스트트랙 지정으로 신속한 허가 기대감이 높아지고 있으며, 임상 3상 진입을 위한 중요한 단계입니다.…more
$2.61-1.13%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report